Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEGA THERAPEUTICS, INC.

(OMGA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OMEGA THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

08/03/2021 | 05:24pm EDT

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On August 3, 2021, Omega Therapeutics, Inc. (the "Company") filed a restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the "IPO") of shares of its common stock. The Company's board of directors and stockholders previously approved the Restated Certificate to be effective immediately after the closing of the IPO.

The Restated Certificate amends and restates the Company's certificate of incorporation in its entirety to, among other things:

(i) fix the authorized number of shares of common stock at 200,000,000 shares; (ii) eliminate all references to the previously existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company's board of directors in one or more series; (iv) establish a classified board of directors, divided into three classes, each of whose members will serve for staggered three-year terms; (v) provide that directors may be removed from office only for cause and only upon the affirmative vote of the holders of at least two-thirds of the Company's capital stock entitled to vote thereon; (vi) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting; (vii) designate the Court of Chancery of the State of Delaware to be the sole and exclusive forum for certain actions, including, but not limited to, derivative actions or proceedings brought on behalf of the Company or actions asserting claims of breach of a fiduciary duty owned by, or other wrongdoing by, any of the Company's directors, officers, employees or agents to the Company or the Company's stockholders, provided that the exclusive forum provision will not apply to actions which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, including actions brought to enforce any liability or duty created by the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the rules and regulations thereunder; and (viii) designate the federal district courts of the United States of America to be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.

The foregoing description of the amendments made by the Restated Certificate is qualified by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

On August 3, 2021, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the "Amended and Restated Bylaws"), previously approved by the Company's board of directors to become effective upon the effectiveness of the Restated Certificate, became effective. The Amended and Restated Bylaws amend and restate the Company's bylaws in their entirety to, among other things, implement certain stockholder protection measures.

The foregoing description of the amendments made in the Amended and Restated Bylaws is qualified by reference to the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

--------------------------------------------------------------------------------

Item 9.01. Financial Statements and Exhibits.


(d) Exhibits



 Exhibit
   No.     Description

 3.1         Restated Certificate of Incorporation of Omega Therapeutics, Inc.

 3.2         Amended and Restated Bylaws of Omega Therapeutics, Inc.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about OMEGA THERAPEUTICS, INC.
10/14OMEGA THERAPEUTICS : Working With Stanford University to Explore Use of Omega Epigenomic C..
MT
10/14OMEGA THERAPEUTICS : Announces Strategic Research Collaboration with Stanford University S..
PR
10/14Omega Therapeutics, Inc. Announces Strategic Research Collaboration with Stanford Unive..
CI
09/27OMEGA THERAPEUTICS : to Present at the Chardan Virtual 5th Annual Genetic Medicines Confer..
PR
09/20OMEGA THERAPEUTICS, INC.(NASDAQGS : OMGA) added to S&P TMI Index
CI
09/10OMEGA THERAPEUTICS' : Q2 Loss Widens as Operating Expenses Rise
MT
09/10OMEGA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
09/10OMEGA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
09/10OMEGA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Outlines Key Corpor..
PR
09/10Omega Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Quarter an..
CI
More news
Analyst Recommendations on OMEGA THERAPEUTICS, INC.
More recommendations